Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.

Luo ilmainen tunnus

Amniotics

Alle 1K seuraajaa

Amniotics develops and manufactures stem cell therapies in our own GMP certified facility. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC). The company is listed at Nasdaq First North Growth Market in Stockholm.

Kaikki

Analyysit

Tiedotteet

NäytäKaikki sisältötyypit

Pörssitiedote23.9.2024 klo 11.30

The Swedish Companies Registration Office has authorised the implementation of the merger plan between Magle group and Amniotics

Lehdistötiedote20.8.2024 klo 11.27

Redeye: Amniotics H1 2024 - Merger with Magle

Pörssitiedote6.8.2024 klo 8.45

Amniotics receives conditional approval to delist from Nasdaq First North Growth Market

Liity Inderesin yhteisöön

Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.

FREE-tili

Pörssin suosituin aamukatsaus

Analyytikon kommentit ja suositukset

Osakevertailu

PREMIUM-tili

Kaikki yhtiöraportit ja sisällöt

Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)

Mallisalkku

Luo ilmainen tunnus

Pörssitiedote6.8.2024 klo 6.45

Amniotics applies for delisting from Nasdaq First North Growth Market conditional upon completion of the merger with Magle Group

Pörssitiedote1.7.2024 klo 15.30

Amniotics publishes merger document regarding the merger with Magle Group

Pörssitiedote30.5.2024 klo 18.05

Statement from the Board of Directors of Amniotics regarding the merger with Magle Group

Pörssitiedote30.5.2024 klo 18.00

Magle Group and Amniotics merge to create a leader in high-quality life-changing healthcare innovations with a broadened CDMO offering

Pörssitiedote21.5.2024 klo 19.50

Amniotics secures continued short-term capital needs by extending loan agreement and continued services under service agreement

Pörssitiedote22.3.2024 klo 6.40

Statement from the Board of Directors of Amniotics regarding the public offer from Magle Chemoswed

Pörssitiedote21.3.2024 klo 17.00

Amniotics secures short-term capital needs by extending loan agreement and entering into a service agreement

Pörssitiedote11.3.2024 klo 15.00

Amniotics announces the outcome of the exercise of warrants series TO 3

Pörssitiedote26.2.2024 klo 7.30

The exercise period for warrants series TO 3 in Amniotics begins today

Lehdistötiedote26.2.2024 klo 6.57

Redeye: Amniotics Q4 2023 - Investigator-sponsored trial in lung transplantation needs funding

Pörssitiedote22.2.2024 klo 14.05

Amniotics AB (publ) Report for the fourth quarter 2023.

Lehdistötiedote21.12.2023 klo 13.16

Information about the Annual General Meeting and appointed Nomination Committee of Amniotics

Pörssitiedote14.12.2023 klo 10.20

Amniotics receives orphan designation for PulmoStem® from the European Commission for the Treatment of Primary Graft Dysfunction following Lung Transplantation

Lehdistötiedote28.11.2023 klo 7.30

Redeye: Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study

Pörssitiedote27.11.2023 klo 7.00

Amniotics AB (publ) Report for the third Quarter 2023

Lehdistötiedote23.11.2023 klo 11.00

Renewed GMP certification

Pörssitiedote20.11.2023 klo 14.40

Amniotics receives positive opinion on orphan designation for PulmoStem® from the European Medicines Agency for the Treatment of Primary Graft Dysfunction following Lung Transplantation

Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.